BIOMAT Database Logo BIOMAT Database Logo

Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. 1991

J W Thüroff, and B Bunke, and A Ebner, and P Faber, and P de Geeter, and J Hannappel, and H Heidler, and H Madersbacher, and H Melchior, and W Schäfer
Department of Urology, Johannes-Gutenberg University Medical School, Mainz, Federal Republic of Germany.

Clinical efficacy and adverse effects of oxybutynin and propantheline in the treatment of symptoms related to detrusor hyperactivity were studied in a randomized, controlled, double-blind multicenter trial. Of 169 patients entered into the study 154 were evaluable for statistical analysis. Mean grade of improvement (visual analogue scale) was significantly higher with oxybutynin (58.2%) versus propantheline (44.7%) and placebo (43.4%). Mean bladder volume at first involuntary cystometric contraction was significantly increased with oxybutynin (+57.0 ml.) versus placebo (-9.7 ml.). Mean maximum cystometric bladder capacity was also significantly increased with oxybutynin (+80.1 ml.) versus placebo (+22.5 ml.). Rate of inquired possible adverse effects was significantly higher for oxybutynin (63%) versus propantheline (44%) and placebo (33%). However, only 5 patients dropped out of the study because of adverse effects (oxybutynin 2 and propantheline 3). No serious or lasting adverse effects were encountered with dryness of the mouth being the major complaint. Oxybutynin has statistically significant effects on subjective symptoms and objective urodynamic parameters in patients with detrusor hyperactivity compared to propantheline.

UI MeSH Term Description Entries
D008297 Male Males
D008333 Mandelic Acids Analogs or derivatives of mandelic acid (alpha-hydroxybenzeneacetic acid). Acids, Mandelic
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009119 Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments. Inotropism,Muscular Contraction,Contraction, Muscle,Contraction, Muscular,Contractions, Muscle,Contractions, Muscular,Inotropisms,Muscle Contractions,Muscular Contractions
D010276 Parasympatholytics Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. Antispasmodic,Antispasmodic Agent,Antispasmodic Drug,Antispasmodics,Parasympathetic-Blocking Agent,Parasympathetic-Blocking Agents,Parasympatholytic,Parasympatholytic Agent,Parasympatholytic Drug,Spasmolytic,Spasmolytics,Antispasmodic Agents,Antispasmodic Drugs,Antispasmodic Effect,Antispasmodic Effects,Parasympatholytic Agents,Parasympatholytic Drugs,Parasympatholytic Effect,Parasympatholytic Effects,Agent, Antispasmodic,Agent, Parasympathetic-Blocking,Agent, Parasympatholytic,Agents, Antispasmodic,Agents, Parasympathetic-Blocking,Agents, Parasympatholytic,Drug, Antispasmodic,Drug, Parasympatholytic,Drugs, Antispasmodic,Drugs, Parasympatholytic,Effect, Antispasmodic,Effect, Parasympatholytic,Effects, Antispasmodic,Effects, Parasympatholytic,Parasympathetic Blocking Agent,Parasympathetic Blocking Agents
D011413 Propantheline A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. Pro-Banthine,Probanthine,Propantheline Bromide,Bromide, Propantheline,Pro Banthine
D001743 Urinary Bladder A musculomembranous sac along the URINARY TRACT. URINE flows from the KIDNEYS into the bladder via the ureters (URETER), and is held there until URINATION. Bladder,Bladder Detrusor Muscle,Detrusor Urinae,Bladder Detrusor Muscles,Bladder, Urinary,Detrusor Muscle, Bladder,Detrusor Muscles, Bladder
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J W Thüroff, and B Bunke, and A Ebner, and P Faber, and P de Geeter, and J Hannappel, and H Heidler, and H Madersbacher, and H Melchior, and W Schäfer
Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
January 2011, BJU international,
J W Thüroff, and B Bunke, and A Ebner, and P Faber, and P de Geeter, and J Hannappel, and H Heidler, and H Madersbacher, and H Melchior, and W Schäfer
Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia.
April 1995, British journal of urology,
J W Thüroff, and B Bunke, and A Ebner, and P Faber, and P de Geeter, and J Hannappel, and H Heidler, and H Madersbacher, and H Melchior, and W Schäfer
Intravesical resiniferatoxin for the treatment of women with idiopathic detrusor overactivity and urgency incontinence: A single dose, 4 weeks, double-blind, randomized, placebo controlled trial.
January 2007, Neurourology and urodynamics,
J W Thüroff, and B Bunke, and A Ebner, and P Faber, and P de Geeter, and J Hannappel, and H Heidler, and H Madersbacher, and H Melchior, and W Schäfer
Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
January 2007, European urology,
J W Thüroff, and B Bunke, and A Ebner, and P Faber, and P de Geeter, and J Hannappel, and H Heidler, and H Madersbacher, and H Melchior, and W Schäfer
Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia.
May 1986, The Journal of urology,
J W Thüroff, and B Bunke, and A Ebner, and P Faber, and P de Geeter, and J Hannappel, and H Heidler, and H Madersbacher, and H Melchior, and W Schäfer
Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.
January 2007, The Journal of urology,
J W Thüroff, and B Bunke, and A Ebner, and P Faber, and P de Geeter, and J Hannappel, and H Heidler, and H Madersbacher, and H Melchior, and W Schäfer
Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial.
November 2010, The Journal of urology,
J W Thüroff, and B Bunke, and A Ebner, and P Faber, and P de Geeter, and J Hannappel, and H Heidler, and H Madersbacher, and H Melchior, and W Schäfer
Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study.
January 2015, Neurourology and urodynamics,
J W Thüroff, and B Bunke, and A Ebner, and P Faber, and P de Geeter, and J Hannappel, and H Heidler, and H Madersbacher, and H Melchior, and W Schäfer
A randomized, double-blind, placebo controlled crossover trial of nimodipine in older persons with detrusor instability and urge incontinence.
February 2002, The Journal of urology,
J W Thüroff, and B Bunke, and A Ebner, and P Faber, and P de Geeter, and J Hannappel, and H Heidler, and H Madersbacher, and H Melchior, and W Schäfer
[Treatment of attention deficit hyperactivity disorder in children: results of a multicenter, randomized, double-blind, placebo-controlled clinical trial].
January 2022, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,
Copied contents to your clipboard!